Stock PDSB PDS BIOTECHNOLOGY CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
3.16 USD +10.49% Intraday chart for PDS Biotechnology Corporation +15.33% -36.42%
06-24 Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer CI
06-12 B. Riley Lowers Price Target on PDS Biotechnology to $9 From $11, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
PDS Biotech Provides Data Update from Ongoing Versatile-002 Phase 2 Clinical Trial in Head and Neck Cancer
CI
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NetScientific says PDS Biotech's Versamune meets endpoints
AN
PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study
MT
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
CI
Empire Metals targets key milestones in Australia
AN
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
PDS Biotechnology Corporation Announces Publication of Preclinical Research
CI
Pds Biotech Announces CFO Changes
CI
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients
CI
PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO
CI
PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer
CI
PDS Biotechnology Corporation Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA
CI
PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies
CI
NetScientific's PDS suffers wider loss as R&D costs mount
AN
PDS Biotechnology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial
CI
PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023
CI
Pds Biotech Announces Acceptance of Abstract on Combination of Pds0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute At Cytokines 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PDSB Stock
  4. News PDS Biotechnology Corporation
  5. Highlights